We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$18.5B
AUM Growth
+$2.83B
Cap. Flow
+$342M
Cap. Flow %
1.85%
Top 10 Hldgs %
16.55%
Holding
2,427
New
891
Increased
366
Reduced
546
Closed
599

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$163M
2
CCL icon
Carnival Corporation Ltd
CCL
+$137M
3
RGEN icon
Repligen
RGEN
+$104M
4
BIIB icon
Biogen
BIIB
+$104M
5
ZTS icon
Zoetis
ZTS
+$91.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.24%
2 Consumer Discretionary 12.89%
3 Financials 10.77%
4 Technology 9.62%
5 Industrials 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PMT
1751
PennyMac Mortgage Investment
PMT
$839M
$178K ﹤0.01%
+10,154
New +$172K
CIXX
1752
DELISTED
CI Financial Corp.
CIXX
$178K ﹤0.01%
+14,400
New +$187K
MG icon
1753
Mistras Group
MG
$495M
$173K ﹤0.01%
22,291
-61,703
-73% -$322K
NESR
1754
National Energy Services Reunited Corp
NESR
$2.71B
$173K ﹤0.01%
17,355
-16,222
-48% -$135K
SIOX
1755
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$171K ﹤0.01%
+61,383
New +$179K
QELL
1756
DELISTED
Qell Acquisition Corp. Class A Ordinary Shares
QELL
$171K ﹤0.01%
+13,878
New +$164K
VSTA
1757
DELISTED
Vasta Platform
VSTA
$170K ﹤0.01%
+11,757
New +$162K
FST
1758
DELISTED
FAST Acquisition Corp.
FST
$170K ﹤0.01%
+16,637
New +$163K
AMCR icon
1759
Amcor
AMCR
$20.9B
$166K ﹤0.01%
+2,817
New +$161K
ZIXI
1760
DELISTED
Zix Corporation
ZIXI
$165K ﹤0.01%
+19,123
New +$136K
TWI icon
1761
Titan International
TWI
$519M
$163K ﹤0.01%
+33,488
New +$137K
AMRX icon
1762
Amneal Pharmaceuticals
AMRX
$5.78B
$160K ﹤0.01%
+34,864
New +$154K
LYRA
1763
DELISTED
LYRA THERAPEUTICS INC
LYRA
$160K ﹤0.01%
+281
New +$158K
OMP
1764
DELISTED
Oasis Midstream Partners LP Common Units Representing Limited Partner Interests
OMP
$159K ﹤0.01%
13,514
-27,254
-67% -$269K
ORMP icon
1765
Oramed Pharmaceuticals
ORMP
$170M
$155K ﹤0.01%
36,632
-22,016
-38% -$71.6K
FCF icon
1766
First Commonwealth Financial
FCF
$2.12B
$154K ﹤0.01%
14,102
-147,909
-91% -$1.42M
TILE icon
1767
Interface
TILE
$1.96B
$153K ﹤0.01%
+14,603
New +$117K
CAN
1768
Canaan Creative
CAN
$192M
$146K ﹤0.01%
24,562
-38,233
-61% -$120K
PERI icon
1769
Perion Network
PERI
$371M
$146K ﹤0.01%
+11,104
New +$98.1K
GPRK icon
1770
GeoPark
GPRK
$615M
$144K ﹤0.01%
+11,073
New +$104K
TRMD icon
1771
TORM
TRMD
$3.05B
$142K ﹤0.01%
19,178
-118,984
-86% -$846K
OPTN
1772
DELISTED
OptiNose
OPTN
$140K ﹤0.01%
2,255
CHU
1773
DELISTED
China Unicom (HONG KONG) Limited
CHU
$139K ﹤0.01%
24,384
+7,600
+45% +$48.1K
RVP icon
1774
Retractable Technologies
RVP
$20.1M
$138K ﹤0.01%
+12,814
New +$124K
IPOF
1775
DELISTED
Social Capital Hedosophia Holdings Corp. VI
IPOF
$135K ﹤0.01%
+10,999
New +$125K

Similar funds

Marshall Wace's Q4 2020 Portfolio in Review

As of Q4 2020, Marshall Wace held 2,427 positions worth $18.5B, up 18% from $15.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Marshall Wace's Q4 2020 filing shows 891 new, 366 increased, 546 reduced and 599 closed positions. Its largest new stake was Natera: 911,254 shares worth $90.7M. The largest sale was Alphabet (Google) Class A, an estimated $173M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Marshall Wace's largest Q4 2020 buy was Natera: 911,254 shares worth $90.7M.
  • Marshall Wace added most to Thermo Fisher Scientific in Q4 2020, an estimated $163M increase.
  • Marshall Wace's biggest Q4 2020 reduction was Alphabet (Google) Class A, cutting an estimated $173M.
  • Marshall Wace fully exited FedEx in Q4 2020, selling an estimated $69.6M.
  • Marshall Wace's ten largest holdings make up 17% of its $18.5B portfolio in Q4 2020.
  • Marshall Wace opened 891 new positions and closed 599 in Q4 2020.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $18.5B.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.